Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Nicole Leite Galvão‐Coelho, Ana Cecília de Menezes Galvão, Raíssa Nóbrega de Almeida, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 10, pp. 1125-1133
Closed Access | Times Cited: 103

Showing 1-25 of 103 citing articles:

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Cato M. H. de Vos, Natasha L. Mason, Kim P. C. Kuypers
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 178
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 164
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants
Nicole Leite Galvão‐Coelho, Wolfgang Marx, Maria Gonzalez, et al.
Psychopharmacology (2021) Vol. 238, Iss. 2, pp. 341-354
Open Access | Times Cited: 122
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 33-46
Closed Access | Times Cited: 4
Inflammatory signaling mechanisms in bipolar disorder
Gregory Jones, Courtney M. Vecera, Omar F. Pinjari, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 85
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers
Jerome Sarris, Daniel Perkins, Lachlan Cribb, et al.
Journal of Affective Disorders Reports (2021) Vol. 4, pp. 100098-100098
Open Access | Times Cited: 57
Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis
Shakila Meshkat, Yazen Alnefeesi, Muhammad Youshay Jawad, et al.
Psychiatry Research (2022) Vol. 317, pp. 114857-114857
Closed Access | Times Cited: 46
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Natasha L. Mason, Attila Szabó, Kim P. C. Kuypers, et al.
Brain Behavior and Immunity (2023) Vol. 114, pp. 299-310
Open Access | Times Cited: 41
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
M. Ishrat Husain, Nicole Ledwos, Elise Fellows, et al.
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 31
Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review
Mario Ignacio Zelada, Verónica Garrido, Andrés Liberona, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14810-14810
Open Access | Times Cited: 30
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis
Arman Shafiee, Razman Arabzadeh Bahri, M. Rafiei, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 5, pp. 425-431
Closed Access | Times Cited: 9
Psychedelics as a novel approach to treating autoimmune conditions
Caitlin Thompson, Attila Szabó
Immunology Letters (2020) Vol. 228, pp. 45-54
Open Access | Times Cited: 63
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective
John R. Kelly, Claire M. Gillan, Jack Prenderville, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 51
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
Rafael G. dos Santos, José Carlos Bouso, Juliana Mendes Rocha, et al.
Risk Management and Healthcare Policy (2021) Vol. Volume 14, pp. 901-910
Open Access | Times Cited: 47
N,N‐dimethyltryptamine and Amazonian ayahuasca plant medicine
Edward James, Joachim Keppler, Thomas L Robertshaw, et al.
Human Psychopharmacology Clinical and Experimental (2022) Vol. 37, Iss. 3
Open Access | Times Cited: 30
Ayahuasca's therapeutic potential: What we know – and what not
Lucas Oliveira Maia, Dimitri Daldegan‐Bueno, Isabel Wießner, et al.
European Neuropsychopharmacology (2022) Vol. 66, pp. 45-61
Closed Access | Times Cited: 29
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action
Rafael G. dos Santos, Jaime EC Hallak, Glen B. Baker, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 453-458
Closed Access | Times Cited: 41
Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers
Juliana Mendes Rocha, Giordano Novak Rossi, Flávia de Lima Osório, et al.
Journal of Clinical Psychopharmacology (2021) Vol. 41, Iss. 3, pp. 267-274
Closed Access | Times Cited: 39
Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach
Igor Magaraggia, Zilla Kuiperes, Rudy Schreiber
Neurobiology of Learning and Memory (2021) Vol. 183, pp. 107467-107467
Open Access | Times Cited: 39
Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments
Brandon Richardson, Andrew J. Macpherson, Francis Rodriguez Bambico
Brain Behavior & Immunity - Health (2022) Vol. 26, pp. 100554-100554
Open Access | Times Cited: 28
Pharmahuasca and DMT Rescue ROS Production and Differentially Expressed Genes Observed after Predator and Psychosocial Stress: Relevance to Human PTSD
D. Parker Kelley, Katy Venable, Aspasia Destouni, et al.
ACS Chemical Neuroscience (2022) Vol. 13, Iss. 2, pp. 257-274
Open Access | Times Cited: 25
Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca
Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e112-e120
Closed Access | Times Cited: 5
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
Zarah R. Haniff, Mariia Bocharova, Tim Mantingh, et al.
Pharmacology & Therapeutics (2024) Vol. 258, pp. 108641-108641
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top